<DOC>
	<DOC>NCT02396251</DOC>
	<brief_summary>A multi-centre, evaluator-blinded study in subjects undergoing cheek augmentation. The study is designed to assess efficacy with regard to aesthetic midface augmentation and safety after treatment with HA product.</brief_summary>
	<brief_title>Evaluation of Efficacy and Safety of Hyaluronic Acid (HA) Product for Cheek Augmentation</brief_title>
	<detailed_description />
	<criteria>Provide a signed and dated informed consent to participate in the study including release of copyright of images Man or woman aged 18 years or older Be willing to abstain from any other facial plastic surgical or cosmetic procedures in close proximity to the treated area Known/previous allergy or hypersensitivity to any injectable HA gel History of bleeding disorder or treatment with anticoagulants, thrombolytics, or inhibitors of platelet aggregation, omega3, or vitamin E within 2 weeks before treatment Treatment with chemotherapy, immunosuppressive agents, immunomodulatory therapy, topical retinoids, systemic or topical corticosteroids within 3 months before treatment and systemic retinoids within 6 months before treatment Previous tissue augmenting therapy or contouring with permanent filler, fatinjection or permanent implant placed in the area to be treated The subject is, in the opinion of the investigator, unlikely to comply with the clinical investigational plan or is unsuitable for any other reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>